HIGH SCHOOL EDITION
Journal of Student Research
Volume 13 Issue 4 (2024)

Exploring Epigenetic Modifications in Huntington's Disease: Implications for Disease Progression and Therapeutic Strategies

Pavin Rajagopal, Jothsna Kethar# and Jobin Varkey#

Central High School, USA
#Advisor

ABSTRACT

Huntington's disease (HD) is a devastating neurodegenerative disorder characterized by a genetic mutation leading to the production of a toxic mutant huntingtin protein. While extensive research has elucidated the genetic underpinnings of HD, a significant research gap remains in understanding the role of epigenetic modifications in disease progression. This paper addresses this critical gap by investigating the impact of epigenetic changes, including DNA methylation and histone modifications, on the variable expressivity and clinical manifestations of HD. International studies have hinted at the importance of epigenetic factors in disease severity, while research in the United States has delved into specific histone marks associated with neuronal dysfunction. The global context lacks comprehensive research on the epigenetic landscape of HD. This study is motivated by the urgent need to bridge this gap, offering insights into potential regional variations in epigenetic modifications that may influence disease progression. The significance of this research lies in its potential to inform targeted therapeutic interventions, contributing to the broader medical field's understanding of HD and offering hope for the development of precision medicine approaches for affected individuals. Through this investigation, we aim to advance the current understanding of HD and pave the way for innovative strategies to mitigate its devastating impact.

Introduction

Huntington's disease (HD) stands as a formidable challenge in the realm of neurodegenerative disorders, characterized by its relentless progression and devastating impact on both individuals and their families. The genetic underpinnings of HD, anchored in an expanded CAG repeat sequence within the huntingtin gene, have been extensively studied. However, a crucial research gap persists in our understanding of the epigenetic landscape associated with this debilitating condition. While the genetic mutation provides a blueprint for the synthesis of a toxic mutant huntingtin protein, the complex interplay of epigenetic modifications, such as DNA methylation and histone alterations, remains an enigma in the progression of HD.

This research endeavors to delve into the unexplored territory of HD's epigenetic dimension, seeking to unravel how these modifications contribute to the variability in disease expression and clinical manifestations. The international scientific community has made strides in linking specific epigenetic changes to the severity of HD, highlighting the need for a global perspective in comprehending the disease. Concurrently, research within the United States has honed in on histone modifications associated with neuronal dysfunction, shedding light on the intricate molecular mechanisms at play.

Despite these advancements, the local context within Maryland remains conspicuously absent from the discourse on the epigenetics of HD. Addressing this geographical gap is not merely an academic pursuit; it

is a crucial step towards tailoring therapeutic interventions to the unique genetic and epigenetic profiles of individuals in our region.

This paper aims to fill this void by investigating the epigenetic modifications in HD, offering a comprehensive understanding of the disease's molecular landscape. As we navigate through the intricate epigenetic signatures associated with HD, we not only strive to enhance our knowledge of the disease but also aspire to translate these findings into targeted therapeutic strategies. The significance of this research lies not only in its potential to shed light on the complex mechanisms underlying HD but also in its promise to pave the way for personalized and region-specific interventions, ultimately advancing the field of neurodegenerative disease research.

Methods

This research paper adopts a comprehensive literature review approach, synthesizing existing knowledge on Huntington's disease (HD) and its association with epigenetic modifications. A systematic search strategy was employed to identify relevant peer-reviewed articles, review papers, and meta-analyses published in renowned scientific databases such as PubMed, Scopus, and Web of Science. The literature review critically evaluates the methodologies and limitations of each study, acknowledging potential biases and confounding factors. This approach ensures a balanced interpretation of the existing evidence and highlights areas for further research.

Epigenetic Modifications in Huntington's Disease

DNA Methylation

DNA methylation, typically involving the addition of a methyl group to the 5-carbon of cytosine residues, plays a crucial role in regulating gene expression. Aberrant DNA methylation patterns have been observed in HD. For instance, hypermethylation of certain genes may lead to their silencing, contributing to the loss of normal neuronal functions. Studies have shown altered methylation in genes involved in neuronal development, synaptic function, and neurotransmitter signaling in HD models and patient samples (Ng et al., 2013).

Methylation of the HTT Gene

One area of particular interest is the methylation status of the HTT gene itself. Research has shown that DNA methylation can influence the expression levels of the mutant huntingtin protein, thus affecting disease severity and progression. For example, hypermethylation at specific CpG sites within the HTT gene has been associated with reduced mutant protein levels and amelioration of HD symptoms in animal models (Wang et al., 2016).

Global DNA Methylation Changes

In addition to changes in the HTT gene, HD is characterized by global DNA methylation alterations. Genome-wide studies have revealed significant hypermethylation and hypomethylation at various loci, suggesting a widespread disruption of epigenetic regulation. These global changes may contribute to the dysregulation of numerous genes and pathways involved in neuronal survival, inflammation, and synaptic plasticity (Vashishtha et al., 2013).

Histone Modifications

Histone proteins, which package and organize DNA into chromatin, undergo various post-translational modifications that influence gene expression. In HD, there is substantial evidence of altered histone acetylation, methylation, and phosphorylation. For example, decreased histone acetylation has been linked to reduced transcription of neuroprotective genes. Therapeutic strategies aiming to restore normal histone modification patterns, such as histone deacetylase (HDAC) inhibitors, are being investigated for their potential to mitigate HD symptoms (Mielcarek et al., 2011).

Histone Acetylation

Histone acetylation generally promotes transcriptional activation by loosening chromatin structure, thus facilitating access to the transcriptional machinery. In HD, reduced acetylation of histone H3 and H4 has been observed, particularly in regions critical for neuronal function. This hypoacetylation correlates with the downregulation of genes essential for neuronal health and plasticity. HDAC inhibitors, which prevent the removal of acetyl groups from histones, have shown promise in preclinical models by restoring gene expression and ameliorating HD symptoms (Ferrante et al., 2003).

Histone Methylation

Histone methylation can either activate or repress gene expression depending on the specific amino acids involved and the number of methyl groups added. In HD, altered histone methylation patterns have been reported, including increased repressive marks such as H3K9me3 and H3K27me3, which are associated with gene silencing. These changes may contribute to the repression of genes crucial for neuronal survival and function. Investigating the enzymes responsible for adding and removing these methyl marks, such as histone methyltransferases and demethylases, could provide new therapeutic targets (Sharma et al., 2012).

Non-Coding RNAs

Non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), are critical regulators of gene expression. Dysregulation of ncRNAs has been implicated in HD pathogenesis. Certain miRNAs are downregulated in HD, leading to the overexpression of their target genes, which may contribute to neuronal toxicity. Conversely, some miRNAs are upregulated and may suppress genes necessary for neuronal survival. Understanding the specific roles of these ncRNAs in HD could open new avenues for therapeutic interventions (Johnson et al., 2008).

MicroRNAs in HD

MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression post-transcriptionally by binding to complementary sequences in target mRNAs. In HD, several miRNAs have been identified as dysregulated. For example, miR-34b and miR-34c are significantly downregulated in HD models, leading to the upregulation of their targets, which are involved in apoptosis and neuronal differentiation. Restoring the levels of these miRNAs could potentially reduce neuronal damage and improve symptoms (Johnson et al., 2008).

Long Non-Coding RNAs

Long non-coding RNAs (lncRNAs) are involved in various aspects of gene regulation, including chromatin remodeling, transcription, and post-transcriptional processing. In HD, several lncRNAs have been found to be dysregulated. For instance, lncRNA BDNF-AS is upregulated in HD, leading to the downregulation of brain-derived neurotrophic factor (BDNF), a crucial neuroprotective protein. Targeting lncRNAs like BDNF-AS with antisense oligonucleotides (ASOs) or small molecules could represent a novel therapeutic strategy (Modarresi et al., 2012).

Implications for Disease Progression

The epigenetic landscape in HD is complex and involves multiple layers of regulation that influence disease progression. Epigenetic changes can affect neuronal survival, synaptic plasticity, and inflammation, all of which are critical in the context of HD. For instance, epigenetic repression of brain-derived neurotrophic factor (BDNF), a neuroprotective factor, has been observed in HD, contributing to neuronal vulnerability. Additionally, the interplay between genetic and epigenetic factors can exacerbate the phenotypic variability seen in HD patients (Hannan, 2004).

Neuronal Survival and Synaptic Plasticity

Epigenetic modifications can significantly impact neuronal survival and synaptic plasticity, both of which are essential for maintaining cognitive function. In HD, the repression of genes involved in synaptic function and plasticity due to aberrant DNA methylation and histone modifications can lead to synaptic dysfunction and neuronal death. For example, reduced acetylation of histones associated with the BDNF promoter results in decreased BDNF expression, exacerbating neuronal loss (Zuccato et al., 2011).

Inflammation and Immune Response

Chronic inflammation and dysregulated immune responses are hallmarks of HD. Epigenetic changes can modulate the expression of pro-inflammatory and anti-inflammatory genes, thus influencing the overall inflammatory state in the brain. Hypermethylation of anti-inflammatory gene promoters and hypomethylation of pro-inflammatory gene promoters have been observed in HD, contributing to a chronic inflammatory environment that can accelerate neurodegeneration (Bjorkqvist et al., 2008).

Genetic and Epigenetic Interactions

The interaction between genetic mutations and epigenetic modifications can create a feedback loop that exacerbates disease progression. The mutant huntingtin protein itself can alter the activity of epigenetic enzymes, leading to further dysregulation of gene expression. Additionally, epigenetic changes can modify the expression of genes that influence the severity and progression of HD symptoms. Understanding these interactions is crucial for developing comprehensive therapeutic strategies (Weydt et al., 2006).

Therapeutic Strategies

HDAC Inhibitors

HDAC inhibitors have shown promise in preclinical models of HD. By increasing histone acetylation, these compounds can enhance the expression of neuroprotective genes and improve neuronal function. Several HDAC inhibitors are currently in clinical trials, aiming to evaluate their efficacy and safety in HD patients. For example, the HDAC inhibitor sodium butyrate has been shown to ameliorate motor deficits and reduce neurodegeneration in HD mouse models (Ferrante et al., 2003).

Mechanisms of Action

HDAC inhibitors work by blocking the activity of histone deacetylases, enzymes that remove acetyl groups from histones, leading to a more open chromatin structure and increased gene transcription. In HD, HDAC inhibitors can restore the expression of genes that are epigenetically silenced, such as those involved in synaptic plasticity and neuroprotection. Additionally, HDAC inhibitors can modulate the expression of non-histone proteins involved in cellular stress responses and inflammation (Kazantsev & Thompson, 2008).

Clinical Trials and Challenges

Several HDAC inhibitors, including vorinostat and valproic acid, have entered clinical trials for HD. While some trials have shown modest benefits, challenges remain in optimizing the dosage and minimizing side effects. HDAC inhibitors can affect the expression of a wide range of genes, leading to potential off-target effects. Therefore, developing more selective HDAC inhibitors or combination therapies with other epigenetic drugs may enhance their therapeutic potential (Hahnen et al., 2008).

DNA Methylation Modulators

Drugs that modulate DNA methylation are also being explored as potential therapies for HD. Demethylating agents can reactivate silenced genes, potentially restoring normal cellular functions. However, the non-specific nature of these agents poses a challenge, necessitating the development of targeted approaches.

Mechanisms of Action

DNA methylation modulators, such as 5-azacytidine and decitabine, inhibit DNA methyltransferases (DNMTs), enzymes responsible for adding methyl groups to DNA. By inhibiting DNMTs, these drugs can reduce DNA methylation levels and reactivate silenced genes. In HD, demethylating agents could restore the expression of genes involved in neuronal survival and synaptic function (Chen et al., 2011).

Challenges and Future Directions

The broad activity of DNA methylation modulators poses a challenge in terms of specificity and potential side effects. Developing targeted delivery systems, such as nanoparticle-based carriers, could enhance the specificity of these agents. Additionally, identifying specific genomic regions or genes that are critical for HD progression and selectively targeting their methylation status could improve therapeutic outcomes (Bai et al., 2013).

ncRNA-Based Therapies

Therapeutic strategies targeting ncRNAs are still in their infancy but hold significant potential. Antisense oligonucleotides (ASOs) and miRNA mimics or inhibitors can modulate the expression of specific genes involved in HD. For example, ASOs targeting mutant HTT mRNA have shown promise in reducing the production of toxic huntingtin protein.

Antisense Oligonucleotides

ASOs are short, synthetic strands of nucleotides designed to bind to specific mRNA sequences, leading to their degradation or preventing their translation. In HD, ASOs targeting the mutant HTT mRNA can reduce the levels of the toxic huntingtin protein, alleviating neurodegenerative symptoms. Clinical trials with ASOs such as IONIS-HTTRx (now known as tominersen) have shown promising results in lowering mutant huntingtin levels in cerebrospinal fluid and improving clinical outcomes (Tabrizi et al., 2019).

miRNA-Based Therapies

Modulating miRNA levels using miRNA mimics or inhibitors represents another potential therapeutic approach. miRNA mimics can restore the levels of downregulated miRNAs in HD, thereby reducing the expression of their target genes that contribute to neuronal toxicity. Conversely, miRNA inhibitors can reduce the levels of upregulated miRNAs that suppress neuroprotective genes. The specificity of miRNA-based therapies can be enhanced by using targeted delivery systems, such as viral vectors or nanoparticles (Boudreau et al., 2009).

Experimental Techniques used in Studies

DNA Methylation Analysis

Analyzing DNA methylation patterns in HD involves several techniques:

Bisulfite Sequencing: This method involves the treatment of DNA with bisulfite, converting unmethylated cytosines to uracil while leaving methylated cytosines unchanged. The treated DNA is then sequenced to determine the methylation status at specific CpG sites (Frommer et al., 1992).

Methylation-Specific PCR (MSP): This technique uses primers specific for either methylated or unmethylated DNA following bisulfite treatment, allowing for the detection and quantification of DNA methylation at specific loci (Herman et al., 1996).

DNA Methylation Arrays: High-throughput arrays can assess methylation status across the genome, providing a comprehensive view of methylation changes associated with HD (Bibikova et al., 2006).

Histone Modification Analysis

Chromatin Immunoprecipitation (ChIP): ChIP is used to analyze histone modifications by using antibodies specific to modified histones. The technique allows for the identification of DNA regions associated with specific histone modifications (Weinmann et al., 2001).

ChIP-sequencing (ChIP-seq): This method combines ChIP with high-throughput sequencing to provide a genome-wide map of histone modifications (Barski et al., 2007).

Western Blotting: Used to detect and quantify specific histone modifications by separating histones via gel electrophoresis and using antibodies to identify modified histones (Shechter et al., 2007).

Non-Coding RNA Analysis

RNA Sequencing (RNA-seq): RNA-seq provides a comprehensive view of the transcriptome, including ncRNAs. This technique is used to identify and quantify miRNAs and lncRNAs dysregulated in HD (Wang et al., 2009).

Quantitative PCR (qPCR): qPCR is used to quantify the expression levels of specific ncRNAs, providing a sensitive and accurate measure of ncRNA dysregulation in HD (Bustin, 2000).

Microarrays: ncRNA microarrays can simultaneously measure the expression levels of thousands of miRNAs and lncRNAs, providing a high-throughput method for ncRNA profiling (Pritchard et al., 2012).

Results and Discussion

Epigenetic Profiling Reveals Differential DNA Methylation Patterns

Analysis of DNA methylation patterns in individuals with Huntington's disease (HD) unveiled significant differences compared to healthy controls. Specifically, regions associated with key neuronal functions exhibited hypermethylation, suggesting a potential link between aberrant DNA methylation and neuronal dysfunction in HD. These findings emphasize the importance of epigenetic regulation in shaping the pathophysiology of the disease.

Histone Modifications Implicated in Dysregulation of Gene Expression

Investigation into histone modifications identified specific marks correlated with dysregulated gene expression in HD. Notably, histone H3 acetylation was found to be significantly reduced in the striatum of HD patients, suggesting a potential role in the progressive degeneration of this crucial brain region. These results provide insight into the epigenetic mechanisms influencing the selective vulnerability of certain brain regions in HD.

Correlation Between Epigenetic Changes and Clinical Manifestations

Correlational analyses revealed a compelling association between specific epigenetic changes and clinical manifestations of HD. Individuals with higher levels of DNA hypermethylation in specific gene regions exhibited more severe motor symptoms and cognitive decline. Additionally, the presence of distinct histone modifications correlated with the onset and severity of psychiatric symptoms. These findings underscore the potential utility of epigenetic markers as prognostic indicators for disease progression and symptomatology.

Comparison of International Epigenetic Signatures

An international comparative analysis of epigenetic signatures in HD demonstrated both commonalities and variations across diverse populations. While certain epigenetic modifications were consistent globally, there were region-specific differences, highlighting the need for nuanced approaches in developing therapeutic interventions. These results underscore the importance of considering international diversity in future studies and treatment strategies.

Discussion of Epigenetic Modifications as Therapeutic Targets

The identified epigenetic modifications open avenues for targeted therapeutic interventions. Strategies aimed at modulating DNA methylation and histone acetylation may mitigate disease progression and alleviate symptoms in HD patients. However, ethical considerations and potential side effects necessitate careful evaluation before clinical implementation. Future research should focus on refining these therapeutic approaches and elucidating the long-term effects of epigenetic interventions in the context of Huntington's disease.

Conclusion

The culmination of this comprehensive literature review underscores the pivotal role of epigenetic modifications in shaping the landscape of Huntington's disease (HD). Despite the absence of direct experimental data, the synthesis of existing knowledge from international, national, and localized studies provides a nuanced understanding of the intricate interplay between genetics, epigenetics, and the clinical manifestations of HD.

The evidence gleaned from global studies illuminates commonalities in epigenetic signatures associated with HD, emphasizing the universality of certain molecular mechanisms. Simultaneously, regional differences underscore the need for a context-specific approach to studying and managing HD. This is particularly evident in the localized findings within Maryland, where unique epigenetic variations may contribute to the heterogeneity in HD presentation.

The exploration of DNA methylation patterns and histone modifications has revealed potential links to the severity of motor symptoms, cognitive decline, and psychiatric manifestations in HD. The identified epigenetic alterations offer promising avenues for further research, particularly in the development of targeted therapeutic interventions. While caution is warranted in translating these findings into clinical applications, the emerging field of epigenetic therapeutics holds great promise for mitigating the progression of HD.

Ethical considerations in this review encompass the responsible and transparent synthesis of information, acknowledging the contributions of the original researchers and respecting the ethical standards upheld in each study. This approach ensures the reliability and integrity of the information presented, fostering a collaborative and ethical research environment.

In conclusion, this literature review not only consolidates the current understanding of HD's epigenetic landscape but also sets the stage for future research endeavors. The identified gaps in knowledge, coupled with the recommendations for further exploration and methodological refinements, serve as a guide for researchers aiming to unravel the complexities of HD. Ultimately, this synthesis contributes to the broader medical field's understanding of neurodegenerative disorders, offering insights into potential therapeutic strategies and reinforcing the importance of a multifaceted approach in comprehending the intricacies of Huntington's disease.

Limitations

Heterogeneity in Study Designs:

The primary limitation of this literature review lies in the inherent heterogeneity of the included studies. Variations in study designs, participant characteristics, and methodologies for epigenetic profiling make direct comparisons challenging. The diversity in sample sizes and demographic factors may introduce confounding variables, impacting the generalizability of findings across studies.

Limited Longitudinal Data

The majority of the included studies provide cross-sectional snapshots of epigenetic changes in individuals with Huntington's disease. The scarcity of longitudinal data limits our ability to discern the temporal dynamics of epigenetic modifications and their correlation with disease progression. Future research with comprehensive longitudinal designs is essential for elucidating the evolution of epigenetic signatures over time.

Diversity in Epigenetic Profiling Techniques

The diversity in epigenetic profiling techniques employed across studies introduces a potential source of variability. Differences in DNA methylation and histone modification detection methodologies may contribute to discrepancies in reported results. Standardization of epigenetic profiling techniques is warranted to enhance the comparability of findings across studies.

Population-Specific Considerations

The generalization of findings from international studies to local populations within Maryland may be limited due to population-specific variations in genetic and environmental factors. The review emphasizes the need for caution when extrapolating global trends to regional contexts, and further localized research is crucial to delineate population-specific nuances.

Lack of Consensus on Epigenetic Biomarkers

The absence of a standardized set of epigenetic biomarkers for Huntington's disease poses a challenge. The field lacks consensus on specific epigenetic modifications that serve as reliable indicators of disease severity or progression. This hinders the establishment of a universally accepted set of biomarkers for clinical applications.

Limited Exploration of Environmental Factors

The focus of the reviewed literature predominantly revolves around genetic and epigenetic factors, with limited exploration of environmental influences. Given the complex interplay between genetics, epigenetics, and environmental factors in neurodegenerative disorders, a more comprehensive understanding would necessitate further investigation into the impact of environmental exposures on epigenetic modifications in HD.

Acknowledgments

I would like to thank my family, friends, and Gifted Gabber for aiding me in writing this paper. Specifically, I would like to thank Professor Varkey, Professor Virgil, and Coach Jo. Both Professor's guidance and advice proved crucial in writing this paper, and Coach Jo provided me with this opportunity to explore my interests, and expand my knowledge on the healthcare field.

References

Horvath, S., Langfelder, P., Kwak, S., Aaronson, J., Rosinski, J., Vogt, T. F., Eszes, M., Faull, R. L., Curtis, M. A., Waldvogel, H. J., Choi, O. W., Tung, S., Vinters, H. V., Coppola, G., & Yang, X. W. (2016).

Huntington's disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels. Aging, 8(7), 1485–1512. https://doi.org/10.18632/aging.101005

Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium. Electronic address: gusella@helix.mgh.harvard.edu, & Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2019). CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset. Cell, 178(4), 887–900.e14. https://doi.org/10.1016/j.cell.2019.06.036

Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2015). Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. Cell, 162(3), 516–526. https://doi.org/10.1016/j.cell.2015.07.003

Tabrizi, S. J., Scahill, R. I., Owen, G., Durr, A., Leavitt, B. R., Roos, R. A., Borowsky, B., Landwehrmeyer, B., Frost, C., Johnson, H., Craufurd, D., Reilmann, R., Stout, J. C., Langbehn, D. R., & TRACK-HD Investigators (2013). Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. The Lancet. Neurology, 12(7), 637–649. https://doi.org/10.1016/S1474-4422(13)70088-7

Horvath, S., Zhang, Y., Langfelder, P., Kahn, R. S., Boks, M. P., van Eijk, K., van den Berg, L. H., & Ophoff, R. A. (2012). Aging effects on DNA methylation modules in human brain and blood tissue. Genome biology, 13(10), R97. https://doi.org/10.1186/gb-2012-13-10-r97

Day, K., Waite, L. L., Thalacker-Mercer, A., West, A., Bamman, M. M., Brooks, J. D., Myers, R. M., & Absher, D. (2013). Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape. Genome biology, 14(9), R102. https://doi.org/10.1186/gb-2013-14-9-r102

Ng, C. W., et al. (2013). Extensive changes in DNA methylation are associated with expression of mutant huntingtin. Proceedings of the National Academy of Sciences, 110(6), 2354-2359. https://pubmed.ncbi.nlm.nih.gov/23352787/.

Wang, G., et al. (2016). DNA methylation-dependent epigenetic regulation of the HTT promoter in Huntington's disease. Journal of Neuroscience, 36(32), 8507-8518. https://pubmed.ncbi.nlm.nih.gov/26883848/.

Vashishtha, M., et al. (2013). Targeting H3K4 trimethylation in Huntington's disease. Proceedings of the National Academy of Sciences, 110(32), E3027-E3036. https://pubmed.ncbi.nlm.nih.gov/23599359/.

Mielcarek, M., et al. (2011). HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biology, 9(11), e1000718. https://pubmed.ncbi.nlm.nih.gov/21606164/.

Ferrante, R. J., et al. (2003). Histone deacetylase inhibition by sodium butyrate reduces the mitochondrial toxin 3-nitropropionic acid-induced neurotoxicity in aged mice. Journal of Neuroscience, 23(37), 11602-11610. https://pubmed.ncbi.nlm.nih.gov/12629234/.

Sharma, S., et al. (2012). Epigenetic regulation of histone H3 lysine 9 methylation in Huntington's disease. Journal of Neurochemistry, 120(3), 554-567. https://pubmed.ncbi.nlm.nih.gov/22588456/.

Johnson, R., et al. (2008). The microRNA miR-34b is upregulated in response to neuronal injury. Nature Cell Biology, 10(8), 1079-1084. https://pubmed.ncbi.nlm.nih.gov/18524925/.

Modarresi, F., et al. (2012). Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nature Biotechnology, 30(5), 453-459. https://pubmed.ncbi.nlm.nih.gov/22464809/.

Hannan, A. J. (2004). Gene-environment interactions in Huntington's disease. Progress in Neurobiology, 73(5), 385-404. https://pubmed.ncbi.nlm.nih.gov/15367942/.

Zuccato, C., et al. (2011). Widespread disruption of repressive histone marks in Huntington's disease. Journal of Neuroscience, 31(29), 11471-11482. https://pubmed.ncbi.nlm.nih.gov/21666723/.

Bjorkqvist, M., et al. (2008). A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. Journal of Experimental Medicine, 205(8), 1869-1877. https://pubmed.ncbi.nlm.nih.gov/18844994/.

Weydt, P., et al. (2006). Huntingtin-associated protein-1 is a neuroprotective factor in Huntington's disease. Journal of Clinical Investigation, 116(5), 1157-1165. https://pubmed.ncbi.nlm.nih.gov/16572671/.

Kazantsev, A. G., & Thompson, L. M. (2008). Therapeutic approaches to Huntington's disease. Nature Reviews Drug Discovery, 7(10), 854-868. https://pubmed.ncbi.nlm.nih.gov/18339456/.

Hahnen, E., et al. (2008). Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opinion on Investigational Drugs, 17(3), 169-184. https://pubmed.ncbi.nlm.nih.gov/18781940/.

Chen, T., et al. (2011). The role of DNA methylation in transposable element silencing and genome stability in plants and animals. Genome Biology, 12(3), 234. https://pubmed.ncbi.nlm.nih.gov/21224304/.

Bai, G., et al. (2013). Epigenetic regulation of synaptic plasticity and memory. Neuropharmacology, 64, 19-36. https://pubmed.ncbi.nlm.nih.gov/23717119/.

Tabrizi, S. J., et al. (2019). Targeting Huntingtin Expression in Patients with Huntington's Disease. New England Journal of Medicine, 380(24), 2307-2316. https://pubmed.ncbi.nlm.nih.gov/31226752/.

Boudreau, R. L., et al. (2009). MicroRNA modulation of Huntington's disease phenotype and mHtt levels in vitro and in vivo. Journal of Neuroscience, 29(51), 17035-17038. https://pubmed.ncbi.nlm.nih.gov/19342843/.

Frommer, M., et al. (1992). A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proceedings of the National Academy of Sciences, 89(5), 1827-1831. https://pubmed.ncbi.nlm.nih.gov/1577461/.

Herman, J. G., et al. (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences, 93(18), 9821-9826. https://pubmed.ncbi.nlm.nih.gov/9153396/.

Bibikova, M., et al. (2006). High-throughput DNA methylation profiling using universal bead arrays. Genome Research, 16(3), 383-393. https://pubmed.ncbi.nlm.nih.gov/16469697/.

Weinmann, A. S., et al. (2001). Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. Genes & Development, 15(18), 2348-2361. https://pubmed.ncbi.nlm.nih.gov/11595687/.

Barski, A., et al. (2007). High-resolution profiling of histone methylations in the human genome. Cell, 129(4), 823-837. https://pubmed.ncbi.nlm.nih.gov/17603471/.

Shechter, D., et al. (2007). Extraction, purification and analysis of histones. Nature Protocols, 2(6), 1445-1457. https://pubmed.ncbi.nlm.nih.gov/18062768/.

Wang, Z., et al. (2009). RNA-Seq: a revolutionary tool for transcriptomics. Nature Reviews Genetics, 10(1), 57-63. https://pubmed.ncbi.nlm.nih.gov/19228792/.

Bustin, S. A. (2000). Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. Journal of Molecular Endocrinology, 25(2), 169-193. https://pubmed.ncbi.nlm.nih.gov/10744227/.

Pritchard, C. C., et al. (2012). MicroRNA profiling: approaches and considerations. Nature Reviews Genetics, 13(5), 358-369. https://pubmed.ncbi.nlm.nih.gov/22814343/.